Eupatilin Ameliorates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting Inflammation, Oxidative Stress, and Apoptosis in Mice.
Kiryeong KimHyo Lim HongGyun-Moo KimJaechan LeemHyun Hee KwonPublished in: Current issues in molecular biology (2023)
Acute kidney injury (AKI) is a common complication of sepsis. Eupatilin (EUP) is a natural flavone with multiple biological activities and has beneficial effects against various inflammatory disorders. However, whether EUP has a favorable effect on septic AKI remains unknown. Here, we examined the effect of EUP on lipopolysaccharide (LPS)-evoked AKI in mice. LPS-evoked renal dysfunction was attenuated by EUP, as reflected by reductions in serum creatinine and blood urea nitrogen levels. LPS injection also induced structural damage such as tubular cell detachment, tubular dilatation, brush border loss of proximal tubules, and upregulation of tubular injury markers. However, EUP significantly ameliorated this structural damage. EUP decreased serum and renal cytokine levels, prevented macrophage infiltration, and inhibited mitogen-activated protein kinase and NF-κB signaling cascades. Lipid peroxidation and DNA oxidation were increased after LPS treatment. However, EUP mitigated LPS-evoked oxidative stress through downregulation of NPDPH oxidase 4 and upregulation of antioxidant enzymes. EUP also inhibited p53-mediated apoptosis in LPS-treated mice. Therefore, these results suggest that EUP ameliorates LPS-evoked AKI through inhibiting inflammation, oxidative stress, and apoptosis.
Keyphrases
- oxidative stress
- acute kidney injury
- inflammatory response
- diabetic rats
- anti inflammatory
- cardiac surgery
- signaling pathway
- lps induced
- dna damage
- ischemia reperfusion injury
- induced apoptosis
- high glucose
- toll like receptor
- cell proliferation
- high fat diet induced
- poor prognosis
- endothelial cells
- long non coding rna
- mouse model
- type diabetes
- hydrogen peroxide
- cell free
- ultrasound guided
- nitric oxide
- pi k akt
- stress induced
- combination therapy
- cell cycle arrest
- metabolic syndrome
- immune response
- uric acid
- protein kinase
- nuclear factor